Erasca, Inc. announced preliminary Phase 1 dose escalation data for ERAS-0015, an oral pan-RAS molecular glue aimed at treating RAS-mutant solid tumors. Early results show favorable safety, tolerability, and pharmacokinetics, with confirmed and unconfirmed partial tumor responses at low doses. ERAS-0015 also targets resistance mechanisms by inhibiting wildtype RAS variants, supporting its potential as a best-in-class therapy. The company will discuss these findings in a webcast on April 27, 2026, signaling progress in precision oncology for RAS-driven cancers.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
